AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32386593 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab (300 mg subcutaneously at baseline, weeks 1, 2, 3, and 4, then every 4 weeks until week 48)
Number of subjects: 853
Study 32386593 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (40 mg every 2 weeks from baseline until week 50)
Number of subjects: 853
Study 32386593 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 853
Study 32386593 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 853
Study 34896242 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP injection in the healing edge and the floor of the targeted DFU (Group A)
Number of subjects: 80
Study 34896242 — intervention group
Group type: COMPARATOR
Intervention: Usual standard care with moist dressing with or without collagenase ointment (Group B)
Number of subjects: 80
Study 35183373 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous golimumab 2 mg/kg every 6 weeks (Q6W)
Number of subjects: 0
Study 35183373 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous golimumab 2 mg/kg every 8 weeks (Q8W)
Number of subjects: 0
Study 32873957 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline supplementation
Number of subjects: 40
Study 32873957 — intervention group
Group type: COMPARATOR
Intervention: Protein-rich diet
Number of subjects: 40
Study 36201327 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive Health Support (PaHS) - telephone-based self-management support
Number of subjects: 6402
Study 36201327 — intervention group
Group type: COMPARATOR
Intervention: Usual universal tax-funded healthcare
Number of subjects: 6402
Study 34008842 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 μg vitamin D3
Number of subjects: 16
Study 34008842 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 μg 25(OH)D3
Number of subjects: 16
Study 32946353 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks for 1 year)
Number of subjects: 1019
Study 32946353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1019
Study 33538956 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPath (intervention group)
Number of subjects: 58
Study 33538956 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 33376581 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting-mimicking diet with low energy-specific meal replacement meals
Number of subjects: 100
Study 33376581 — intervention group
Group type: COMPARATOR
Intervention: Specific meal replacement foods given normal adult doses
Number of subjects: 100
Study 36418984 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care + three units of high‐titre convalescent plasma
Number of subjects: 180
Study 36418984 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care + three units of standard plasma
Number of subjects: 180
Study 36418984 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 180
Study 32189227 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvisational music therapy
Number of subjects: 101
Study 32189227 — intervention group
Group type: EXPERIMENTAL
Intervention: Attunement observed from session videos
Number of subjects: 101
Study 35090722 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 100 μg
Number of subjects: 290
Study 35090722 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 290
Study 34686365 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCD 3 mg/kg
Number of subjects: 30
Study 34686365 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCD 4 mg/kg
Number of subjects: 30
Study 35580819 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic reward (same-day)
Number of subjects: 135
Study 35580819 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipated regret (same-day)
Number of subjects: 135
Study 35580819 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy (same-day)
Number of subjects: 135
Study 35580819 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic reward (between-level)
Number of subjects: 135
Study 35580819 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipated regret (between-level)
Number of subjects: 135
Study 35580819 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy (between-level)
Number of subjects: 135
Study 34087877 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational emotive career education program (12 sessions)
Number of subjects: 61
Study 34087877 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted control group (no intervention)
Number of subjects: 61
Study 32418375 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean section
Number of subjects: 1040
Study 34107477 — intervention group
Group type: EXPERIMENTAL
Intervention: HA380 hemoperfusion cartridge (HP group)
Number of subjects: 60
Study 34107477 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPB circuit (Control group)
Number of subjects: 60
Study 32444570 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT) alongside conventional physiotherapy (30 min/session each, total 60 min/session, 3-4 sessions/week for 30 sessions over 8-10 weeks)
Number of subjects: 75
Study 32444570 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT) alongside conventional physiotherapy
Number of subjects: 75
Study 35643360 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie Restricted (CR) diet
Number of subjects: 88
Study 32757311 — intervention group
Group type: EXPERIMENTAL
Intervention: Socket shield technique with immediate temporization
Number of subjects: 40
Study 32757311 — intervention group
Group type: COMPARATOR
Intervention: Immediate implant placement with immediate temporization
Number of subjects: 40
Study 33137754 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexterity Network (Dex-Net) 4.0 policy using ambidextrous grippers
Number of subjects: 1
Study 33501773 — intervention group
Group type: EXPERIMENTAL
Intervention: Consent to randomization in AALL0932
Number of subjects: 0
Study 32203692 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 0
Study 32203692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36038164 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT with BED10 of 60-70 Gy combined with gemcitabine plus albumin-bound paclitaxel
Number of subjects: 0
Study 36038164 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT with BED10 >70 Gy combined with gemcitabine plus albumin-bound paclitaxel
Number of subjects: 0
Study 33835198 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports compression garment (CG) (28.6 ± 9.4 mmHg)
Number of subjects: 13
Study 33835198 — intervention group
Group type: COMPARATOR
Intervention: Gymnastic pants (CON)
Number of subjects: 13
Study 35932279 — intervention group
Group type: EXPERIMENTAL
Intervention: STRIDE intervention (multifactorial intervention delivered by trained registered nurses)
Number of subjects: 5451
Study 35932279 — intervention group
Group type: EXPERIMENTAL
Intervention: STRIDE intervention
Number of subjects: 5451
Study 35938328 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Sanyinjiao (SP 6) and Guanyuan (CV 4), once a day starting 5-7 days before menstrual flow for 3 menstrual cycles.
Number of subjects: 42
Study 35938328 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group).
Number of subjects: 42
Study 33833857 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) treatment
Number of subjects: 0
Study 32015684 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE)
Number of subjects: 81
Study 32015684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 35895484 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve-guided percutaneous coronary intervention with new-generation drug-eluting stents
Number of subjects: 1500
Study 35895484 — intervention group
Group type: COMPARATOR
Intervention: Coronary bypass surgery
Number of subjects: 1500
Study 34577457 — intervention group
Group type: EXPERIMENTAL
Intervention: Garmin Vivoactive 4s
Number of subjects: 28
Study 34577457 — intervention group
Group type: EXPERIMENTAL
Intervention: Garmin Vivosport
Number of subjects: 28
Study 34577457 — intervention group
Group type: EXPERIMENTAL
Intervention: Polar Vantage M
Number of subjects: 28
Study 34577457 — intervention group
Group type: EXPERIMENTAL
Intervention: All trackers
Number of subjects: 28
Study 33040112 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation with Miller blade in E+ group (oesophageal intubation simulated)
Number of subjects: 120
Study 33040112 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal intubation with Miller blade in E- group (standard procedure)
Number of subjects: 120
Study 33040112 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation with Macintosh blade in E+ group
Number of subjects: 120
Study 33040112 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal intubation with Macintosh blade in E- group
Number of subjects: 120
Study 33040112 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation with video laryngoscope in E+ group
Number of subjects: 120
Study 33040112 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal intubation with video laryngoscope in E- group
Number of subjects: 120
Study 33040112 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of task difficulty for both groups (E+ and E-)
Number of subjects: 120
Study 34169482 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal exercise (OPE) in addition to CPAP therapy
Number of subjects: 41
Study 35000358 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided infraclavicular block (IB)
Number of subjects: 60
Study 35000358 — intervention group
Group type: COMPARATOR
Intervention: Procedural sedation and analgesia (PSA)
Number of subjects: 60
Study 34185862 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based medical emergency preparedness curriculum
Number of subjects: 16
Study 34185862 — intervention group
Group type: COMPARATOR
Intervention: Standard curriculum
Number of subjects: 16
Study 35113938 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (aerobic and resistance training) for 12 weeks
Number of subjects: 38
Study 33294966 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-theory-informed psychotherapeutic intervention
Number of subjects: 0
Study 34860575 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitiered system of language support (MTSLS) using Story Champs for 14 weeks, with Tier 1 instruction for 15-20 min a day for 4 weeks followed by Tier 2 intervention for 20 min twice a week for students who did not make adequate progress.
Number of subjects: 686
Study 34860575 — intervention group
Group type: EXPERIMENTAL
Intervention: Tier 2 intervention of Story Champs for at-risk students (n = 49)
Number of subjects: 686
Study 33417506 — intervention group
Group type: EXPERIMENTAL
Intervention: eRAPID (weekly online symptom reporting for 18 weeks)
Number of subjects: 508
Study 33417506 — intervention group
Group type: EXPERIMENTAL
Intervention: eRAPID
Number of subjects: 508
Study 33417506 — intervention group
Group type: COMPARATOR
Intervention: usual care (UC)
Number of subjects: 508
Study 32224483 — intervention group
Group type: EXPERIMENTAL
Intervention: iCAN‐DO internet-based stepped care program
Number of subjects: 15
Study 36493386 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg THC + 0 mg CBD
Number of subjects: 46
Study 36493386 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg THC + 10 mg CBD
Number of subjects: 46
Study 36493386 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg THC + 20 mg CBD
Number of subjects: 46
Study 36493386 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg THC + 30 mg CBD
Number of subjects: 46
Study 36493386 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mg THC and CBD)
Number of subjects: 46
Study 34080015 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC)
Number of subjects: 2
Study 34080015 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) + Environmental Enrichment (EE)
Number of subjects: 2
Study 34080015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 32289634 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (200,000 IU for the first 2 months, then 100,000 IU monthly for 18 months)
Number of subjects: 313
Study 32289634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 34788380 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy individuals
Number of subjects: 39
Study 34788380 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanically ventilated patients
Number of subjects: 39
Study 33167092 — intervention group
Group type: EXPERIMENTAL
Intervention: TRXR1 siRNA interference group 1 (transfected with TRXR1‐siRNA1)
Number of subjects: 76
Study 33167092 — intervention group
Group type: EXPERIMENTAL
Intervention: TRXR1 siRNA interference group 2 (transfected with TRXR1‐siRNA2)
Number of subjects: 76
Study 33167092 — intervention group
Group type: COMPARATOR
Intervention: Negative control group (transfected with NC‐siRNA)
Number of subjects: 76
Study 35531965 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbol Digit Modalities Test (SDMT)
Number of subjects: 275
Study 35531965 — intervention group
Group type: EXPERIMENTAL
Intervention: SDMT z score
Number of subjects: 275
Study 33069623 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage BMGU
Number of subjects: 135
Study 35152915 — intervention group
Group type: EXPERIMENTAL
Intervention: Phantom motor execution (PME)
Number of subjects: 67
Study 33388032 — intervention group
Group type: EXPERIMENTAL
Intervention: Single general practice attendance
Number of subjects: 0
Study 33388032 — intervention group
Group type: COMPARATOR
Intervention: Multiple general practice attendance
Number of subjects: 0
Study 35426283 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose TXA (20 mg/kg)
Number of subjects: 116
Study 35426283 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose TXA (50 mg/kg)
Number of subjects: 116
Study 35426283 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled (normal saline)
Number of subjects: 116
Study 34003418 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 409
Study 33071253 — intervention group
Group type: EXPERIMENTAL
Intervention: Coelioscopic‐assisted ovariosalpingectomy using a digital otoscope (right prefemoral access)
Number of subjects: 20
Study 33071253 — intervention group
Group type: EXPERIMENTAL
Intervention: Coelioscopic‐assisted ovariosalpingectomy using a digital otoscope (left prefemoral access)
Number of subjects: 20
Study 33071253 — intervention group
Group type: COMPARATOR
Intervention: Coelioscopic‐assisted ovariosalpingectomy using a digital otoscope (both groups)
Number of subjects: 20
Study 35189082 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir dispersible tablets (5 mg, 10 mg, 15 mg, 20 mg based on weight bands)
Number of subjects: 72
Study 35189082 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 25 mg film-coated tablets
Number of subjects: 72
Study 35189082 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall safety evaluation
Number of subjects: 72
Study 33503531 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal sterile water injection (ISWI) combined with systemic intravenous dexketoprofen therapy
Number of subjects: 112
Study 33503531 — intervention group
Group type: COMPARATOR
Intervention: Systemic intravenous dexketoprofen therapy alone
Number of subjects: 112
Study 36344654 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab and Erlotinib (AE)
Number of subjects: 60
Study 36344654 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (A)
Number of subjects: 60
Study 34247300 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychoeducational intervention for grandparents; 6-hour intervention program.
Number of subjects: 120
Study 32538561 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP assisted reconstruction of 3‐strand peroneal longus tendons
Number of subjects: 58
Study 32538561 — intervention group
Group type: COMPARATOR
Intervention: 4‐strand hamstring tendon reconstruction alone
Number of subjects: 58
Study 35662124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation intervention mediated with new technologies (16 sessions including attention, executive function, and memory tasks)
Number of subjects: 98
Study 35662124 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 98
Study 35662124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation intervention
Number of subjects: 98
Study 35550441 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+ selection and post‐transplantation cyclophosphamide
Number of subjects: 0
Study 35550441 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus/methotrexate (Tac/MTX)
Number of subjects: 0
Study 35815358 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine
Number of subjects: 0
Study 35815358 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine
Number of subjects: 0
Study 35815358 — intervention group
Group type: COMPARATOR
Intervention: EudraVigilance
Number of subjects: 0
Study 33663132 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based educational intervention
Number of subjects: 0
Study 33663132 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32685542 — intervention group
Group type: EXPERIMENTAL
Intervention: Conbercept treatment (initial intravitreal injection followed by PRN strategy)
Number of subjects: 60
Study 32685542 — intervention group
Group type: EXPERIMENTAL
Intervention: Conbercept treatment
Number of subjects: 60
Study 32685542 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 60
Study 35393631 — intervention group
Group type: EXPERIMENTAL
Intervention: dupilumab ± topical corticosteroids
Number of subjects: 471
Study 33947965 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 0
Study 33947965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32663479 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive training program (twice weekly for 12 weeks, 55 minutes per session)
Number of subjects: 42
Study 32663479 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive training program
Number of subjects: 42
Study 32663479 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy intervention program (45 minutes group + 100 minutes individual per week for 12 weeks)
Number of subjects: 42
Study 34309736 — intervention group
Group type: EXPERIMENTAL
Intervention: Splinting before full-mouth disinfection (FMD)
Number of subjects: 34
Study 34309736 — intervention group
Group type: COMPARATOR
Intervention: Splinting after full-mouth disinfection (FMD)
Number of subjects: 34
Study 34309736 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 34
Study 34257959 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) at 1200 mg every 12 hours for 48 hours
Number of subjects: 64
Study 34257959 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64
Study 34257959 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 64
Study 35605807 — intervention group
Group type: EXPERIMENTAL
Intervention: Organ transplantation
Number of subjects: 4178
Study 35605807 — intervention group
Group type: COMPARATOR
Intervention: Steroid use
Number of subjects: 4178
Study 34877262 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided Internet-delivered intervention for coping with ADHD (N = 59)
Number of subjects: 118
Study 34877262 — intervention group
Group type: COMPARATOR
Intervention: Self-guided online psychoeducation (control group, N = 59)
Number of subjects: 118
Study 34686624 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR) training during resistance exercises
Number of subjects: 20
Study 34686624 — intervention group
Group type: COMPARATOR
Intervention: Exercises alone (Control)
Number of subjects: 20
Study 35982485 — intervention group
Group type: EXPERIMENTAL
Intervention: ImpACT + intervention (six once-a-week coping intervention sessions and six monthly maintenance sessions)
Number of subjects: 350
Study 35982485 — intervention group
Group type: COMPARATOR
Intervention: Control condition (three weekly sessions of adapted problem-solving therapy)
Number of subjects: 350
Study 33982092 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating linoleic acid (LA)
Number of subjects: 33126
Study 33982092 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher genetically predicted circulating arachidonic acid (AA)
Number of subjects: 33126
Study 32954846 — intervention group
Group type: EXPERIMENTAL
Intervention: Volatile Organic Products (VOPs)
Number of subjects: 30
Study 36072875 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybutimibe plus atorvastatin
Number of subjects: 255
Study 36072875 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 255
Study 33558344 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional care intervention performed by geriatric-experienced care professionals for up to 12 months, including an individual care plan, personal visits, and telephone contacts.
Number of subjects: 0
Study 33558344 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional care intervention
Number of subjects: 0
Study 33558344 — intervention group
Group type: COMPARATOR
Intervention: Usual discharge planning and usual ambulatory care (Control group)
Number of subjects: 0
Study 35557075 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (spinning at 85% of maximal heart rate reserve)
Number of subjects: 42
Study 35557075 — intervention group
Group type: COMPARATOR
Intervention: Stretching (active control intervention)
Number of subjects: 42
Study 34002642 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapeziectomy with or without ligament reconstruction with tendon interposition
Number of subjects: 18
Study 34002642 — intervention group
Group type: COMPARATOR
Intervention: Total joint arthroplasty using a Touch® implant
Number of subjects: 18
Study 34002642 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated trapeziectomy
Number of subjects: 18